Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 13,615 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Completed Phase 3 Interventional

Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer

NCT00003855
View directory record Official record
Conditions
Breast Cancer
Interventions
axillary lymph node dissection, whole breast irradiation
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

NCT01138085
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2141795
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea

NCT02095158
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
Oxymetazoline HCL Cream 1.0%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 31, 2026, 1:42 PM EDT
Terminated Phase 4 Interventional Results available

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

NCT05710185
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Deucravacitinib
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00006385
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interferon alfa, sargramostim, tyrosinase peptide
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
32
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

NCT00689117
View directory record Official record
Conditions
Acne Vulgaris, Acne
Interventions
CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
1,649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 31, 2026, 1:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

NCT00609791
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study, physiologic testing, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, psychosocial assessment and care
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Collaborative Connected Health (CCH) for PCORI

NCT02358135
View directory record Official record
Conditions
Psoriasis
Interventions
Collaborative Connected health, (CCH), Control
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

NCT03075540
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
Genetic Counseling and Testing YouTube Video
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Not applicable Interventional Results available

The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease

NCT01687790
View directory record Official record
Conditions
Breast Abnormalities
Interventions
molecular breast imaging (Discovery)
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Oct 31, 2026, 1:42 PM EDT
Active, not recruiting Not applicable Interventional

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

NCT02515110
View directory record Official record
Conditions
Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
Interventions
External Beam Radiation Therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Richmond, Virginia • South Hill, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

EMBRACE: Exercising Together

NCT06049355
View directory record Official record
Conditions
Breast Carcinoma, Prostate Carcinoma
Interventions
Exercise Intervention, Biospecimen Collection, Educational Intervention
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

NCT00498615
View directory record Official record
Conditions
Raynaud, Scleroderma
Interventions
Fasudil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 31, 2026, 1:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

NCT05074290
View directory record Official record
Conditions
Breast Cancer
Interventions
Epidiferphane, Taxane Chemotherapy
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Terminated No phase listed Observational

Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer

NCT01975597
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Bone marrow aspirates and biopsy
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 31, 2026, 1:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining the Long-Term Risks of Oophorectomy

NCT00655447
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Breast Cancer, Ovarian Cancer, Cancer, Hip Fracture, Death
Interventions
Not listed
Lead sponsor
Parker, William H., M.D.
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
32,175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1980 – 2004
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Oct 31, 2026, 1:42 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

NCT02985658
View directory record Official record
Conditions
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Interventions
Veliparib, Cisplatin, Vinorelbine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Not applicable Interventional Results available

Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers

NCT05579743
View directory record Official record
Conditions
Diabetic Foot, Diabetic Foot Ulcer, Wound; Foot, Wound Leg, Wound Heal, Diabetes Complications
Interventions
Remote wound monitoring technology
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 31, 2026, 1:42 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Recruiting Phase 2 Interventional

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

NCT07155317
View directory record Official record
Conditions
Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Acral Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 31, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

NCT05071664
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Golimumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Searcy, Arkansas • Avon Park, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 31, 2026, 1:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

NCT01447199
View directory record Official record
Conditions
Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Skin Cancer, Uterus Cancer
Interventions
Health and Diet Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 31, 2026, 1:42 PM EDT